NIPT Premaitha

TIDMYGEN

Yourgene Health PLC

24 September 2020

Yourgene Health plc

("Yourgene" or the "Company")

DPD reimbursement in Germany

Manchester, UK - 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that the German Federal Joint Committee, G-BA, the national reimbursement authority in Germany, has approved the reimbursement for testing of Dihydropyrimidine Dehydrogenase (DPD) deficiency in Germany, which opens up the clinical market in this region for the Company's first oncology genotyping product, the Elucigene DPYD Test. The preliminary reimbursement figure for DPD testing is set at 120 EUR for each patient test. The scheme commences on the 1 October 2020 and has not at this stage specified any commercial products or technologies.

Elucigene DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of colon, oesophageal, stomach, pancreatic, breast and cervical cancers. 5-FU is metabolized by the DPD enzyme which is encoded by the DPYD gene.

The Committee for Risk Assessment in the field of pharmacovigilance of the European Medicines Agency and the Federal Institute for Medicinal Products and Medical Devices have determined the benefits of the DPD test, highlighting patients with an absence or deficiency of the DPD enzyme to have an increased risk of severe or life threatening toxicity. The reimbursement will fall under the EBM scheme, which covers the largest number of patients (approx. 80% of the population).

Lyn Rees, CEO of Yourgene Health said: "We expect this reimbursement approval to help accelerate our growth in this key market, aided by having a direct sales presence, enabling us to capitalise on this opportunity."

 
Yourgene Health plc                                                 Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                             investors@yourgene-health.com 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
Cairn Financial Advisers LLP (NOMAD)                                Tel: +44 (0)20 7213 0880 
Liam Murray / James Caithie / Ludovico 
 Lazzaretti 
 
N+1 Singer (Joint Corporate Broker)                                 Tel: +44 (0)20 7496 3000 
Aubrey Powell / Tom Salvesen / George 
 Tzimas 
 
Stifel Nicolaus Europe Limited (Joint                               Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
 
 
Walbrook PR Ltd (Media and Investor      Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations) 
 Paul McManus / Lianne Cawthorne                             Mob: 07980 541 893 / Mob: 07584 
                                                                                     391 303 
 
 
 

About Yourgene Health plc

Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and molecular genetics. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.

Yourgene is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.

END

NRAZZGZLRDRGGZG

(END) Dow Jones Newswires

September 24, 2020 05:00 ET (09:00 GMT)

Grafico Azioni Premaitha (LSE:NIPT)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Premaitha (LSE:NIPT)
Storico
Da Giu 2023 a Giu 2024